Gotistobart Nearly Doubles Median Overall Survival in Squamous NSCLC — 18.5 vs 10.0 Months
BNTX sits 29% above its 52-week low of $79.52.
Summary
Gotistobart showed 18.5 months median overall survival versus 10.0 months for chemotherapy in previously treated squamous NSCLC, nearly doubling survival with a manageable safety profile.
Key Events · Product Development and Regulatory · BNTX
-
Median OS Nearly Doubled
Gotistobart achieved 18.5 months median overall survival versus 10.0 months for docetaxel (HR 0.56, nominal p=0.0295) in 87 randomized patients with previously treated squamous NSCLC.
-
Manageable Safety Profile
Grade ≥3 treatment-related adverse events occurred in 44.4% of gotistobart patients versus 48.8% for docetaxel, consistent with previously reported data.
-
Pivotal Stage 2 Ongoing
The registrational stage 2 portion of PRESERVE-003 is enrolling at more than 160 sites globally; this stage 1 data supports the ongoing pivotal readout.
-
Pipeline Context
This positive data follows the August 2026 termination of the Phase 2 colorectal cancer trial for autogene cevumeran and a ~20% cut to 2026 revenue guidance, providing a needed oncology catalyst.
Analysis · BNTX · Life Sciences
The first median overall survival data from the non-pivotal stage 1 of the PRESERVE-003 Phase 3 trial were presented by BioNTech and OncoC4. In previously treated squamous NSCLC, gotistobart achieved 18.5 months median OS versus 10.0 months for docetaxel (HR 0.56, nominal p=0.0295). This is a statistically significant and clinically meaningful survival benefit in a setting where standard of care has remained chemotherapy for over a decade. The pivotal stage 2 portion is ongoing at more than 160 sites globally, so this data is a strong signal for the registrational readout. The safety profile was manageable, with Grade ≥3 treatment-related AEs in 44.4% of gotistobart patients versus 48.8% for docetaxel. This comes at a critical time for BioNTech, which recently cut 2026 revenue guidance and terminated its Phase 2 colorectal cancer trial for autogene cevumeran — a positive oncology data point helps offset that negative pipeline news.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 40% of the 995 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BNTX was trading at $102.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.3B. The 52-week trading range was $79.52 to $124.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.